Claus Braestrup - Evotec AG Insider

Evotec AG -- USA Stock  

USD 20.35  0.00  0.00%

Member of the Supervisory Board

Dr. Claus T. Braestrup, M.D., was Member of the Supervisory Board of Evotec AG since June 12, 2013. He is Member of the Audit Committee at the Company. During his career, he gained experience from publicly traded international pharmaceutical companies as well as scientific and drug discovery qualifications. From 2003 to 2008, he served as President and CEO at H. Lundbeck AS, where he was head of research and development from 1998 to 2003. Previously, he served as head of preclinical drug research at Schering AG from 1994 to 1998, at Novo Nordisk AS as president of the Diabetes Care Division, President of its CNS Division and Vice President of pharmaceutical research and at Ferrosan AS as scientist in drug discovery from 1978 to 1984. He serves as Chairman of the Board of Saniona AB and as Member of the Board of Bavarian Nordic AS, Kastan ApS and Evolva SA. He holds a Masters degree in Chemical Engineering and is MS in Biochemistry. He is Doctor of Medical Science and former Adjunct Professor in Neuroscience at the University of Copenhagen.
Age: 71  Executive Since 2013      
49 40 5 60 81 0

Management Efficiency

The company has return on total asset (ROA) of 4.56 % which means that it generated profit of $4.56 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 11.13 % meaning that it generated $11.13 on every $100 dollars invested by stockholders.
The company has accumulated 213.13 M in total debt with debt to equity ratio (D/E) of 53.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Evotec AG has Current Ratio of 0.68 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.

Similar Executives

Entity Summary

Evotec AG provides drug discovery solutions to the pharmaceutical and biotechnology companies, academic institutions, and foundations and not-for-profit organizations worldwide. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany. Evotec AG is traded on OTC Market in USA.Evotec AG (EVOTF) is traded on OTC Market in USA. It is located in Manfred Eigen Campus and employs 1,238 people.

Fix Portfolio

Optimize Your Risk-Return Tradeoff
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Evotec AG to your portfolio

Top Management

Evotec AG Leadership Team
Werner Lanthaler, CEO
Claus Braestrup, Executive
Michael Shalmi, Executive, MBA
Mario Polywka, COO, Ph.D
Mary Tanner, Executive
Roland Oetker, Chairman
Andreas Pinkwart, Executive
Paul Herrling, Executive, Ph.D
Colin Bond, CFO, MBA
Cord Dohrmann, Executive
Iris LoewFriedrich, Executive, Ph.D
Bernd Hirsch, Executive
Enno Spillner, CFO
Elaine Sullivan, Executive
Wolfgang Plischke, Chairman, Ph.D

Stock Performance

Evotec AG Performance Indicators